Table 1.
Summary of data upon hormonal therapy used for the treatment of ESS.
| Early Stage | ||||||
| Study (Year) | Type of Study | Number of Patients | Setting | Treatment | Results | Response |
| Katz et al. (1987) [25] | Case series | 2 | Adjuvant | MA | NED | Response duration: 24–72 months |
| Malouf et al. (2010) [28] | Retrospective study | 4 | Adjuvant | MA | 4 NED | NA |
| Both early and advanced stage | ||||||
| Study (year) | Type of study | Number of patients | Setting | Treatment | Results | Response |
| Chu et al. (2003) [26] | Retrospective study | 13–8 | Adjuvant–Metastatic | MA/NSP | 9 NED/4 recurred–4 CR/3 SD/1 PD | Response duration: 18–180 months |
| Cheng et al. (2011) [18] | Retrospective study | 25–30 | Adjuvant–Metastatic | NSP | 25 NED–5 CR/3 PR/16 SD/6 PD 10-year PFS rate: 43% 10-year OS rate: 85% ORR: 27%; median TTP: 24 months |
10-year PFS rate: 43% 10-year OS rate: 85% ORR: 27%; median TTP: 24 months |
| Advanced disease | ||||||
| Study (year) | Type of study | Number of patients | Setting | Treatment | Results | Response |
| Friedlander et al., 2019 [44] |
Phase II, Open label |
15 | Advanced/ Metastatic |
Anastrozole | 1 CR/3 PR/7 SD CBR at 3 months: 73% Median PFS not reached ORR 26.7% |
CBR at 3 months: 73% Median PFS not reached ORR 26.7% |
| Pink et al. (2006) [30] | Case series | 8 | Advanced/ Metastatic |
MPA | 1 CR/1 SD/1 PD | Response duration: 9–50 months |
| 5 Letrozole | 4 PR/1 PD | Response duration: 3–37 months |
||||
| Dahhan et al. (2009) [31] | Retrospective study | 11 | Advanced/ Metastatic |
MA | 4 CR/3 PR/1 SD | Response duration: 4–252 months |
| 3 Letrozole | 2 PR/1 PD | |||||
| Ioffe et al. (2009) [29] | Retrospective study | 8 | Advanced/ Metastatic |
MA/MPA | 1 PR/3 SD/1 PD | Response duration: 6–124 months |
| 3 Letrozole | 2 PR/1 CR | |||||
| Mizuno et al. (2012) [33] | Case series | 6 | Advanced/ Metastatic |
MPA | 3 PR/3SD | After 6 months of therapy: overall response rate: 50%; disease control rate: 100%. |
| Yamazaki et al. (2015) [32] | Retrospective study | 9 | Advanced/ Metastatic |
MPA DDG GnRHa |
3 CR/2 PR/1 SD/2 PD/1 NA | Response rate: 63.6%. Disease control rate 72.7% |
| Spano et al. (2003) [39] | Case series | 2 | Advanced/ Metastatic |
2 Aminoglutethimide | 2 CR | Response duration: 84–168 months |
| Altman et al. (2012) [77] | Retrospective study | 4 | Advanced/ Metastatic |
4 Anastrozole (1 switched to Letrozole, 1 to Exemestane) | 3 SD/1 PR | NA |
| Ryu et al. (2015) [42] | Case series | 2 | Advanced/ Metastatic |
2 Letrozole | 2 CR | Response duration: 3–124 months |
| Yamagushi et al. (2015) [43] | Retrospective study | 5 | Advanced/ Metastatic |
5 Letrozole | 1 PR/2 CR/2 SD | Time to recurrence (TTR) range: 42–192 months |
MA: megestrol acetate; NED: no evidence of disease; CR: complete response; NSP: not specified progestins; PR: partial response; MPA: medroxyprogesterone acetate; DDG: dydrogesterone; GnRHa: gonadotropin-releasing hormone analogues; SD: stable disease; PD: progression of disease; CBR: clinical benefit rate; PFS: progression-free survival; ORR: overall response rate NA: not available.